Astellas discontinues EGFR inhibitor

Astellas Pharma Inc. (Tokyo:4503) discontinued development of ASP8273 to treat non-small cell lung cancer (NSCLC). The EGFR inhibitor was in the Phase III SOLAR trial in the indication. Spokesperson Tyler Marciniak told BioCentury an IDMC's analysis determined that clinical data suggested the therapy "may have lower benefit relative to risk than the control arm."...